<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515018</url>
  </required_header>
  <id_info>
    <org_study_id>FirstAHHMU</org_study_id>
    <nct_id>NCT03515018</nct_id>
  </id_info>
  <brief_title>Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients</brief_title>
  <acronym>HU</acronym>
  <official_title>Evaluation of the Therapeutic Effect of Hydroxyurea Pulse Therapy for Chronic Myeloid Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chronic-phase chronic myelogenous leukemia (CML) aimed to avoid CML
      conversion (AP, BC). Hydroxyurea pulse therapy for chronic-phase CML patients is effective
      based on the investigator's previous studies, and the scheme cost lower than imatinib. It is
      not yet known the efficacy compared Hydroxyurea pulse therapy with imatinib for chronic-phase
      CML, especially to achieve hematological remission in short time.

      PURPOSE: Non-randomized trial to compare the effectiveness of hydroxyurea pulse therapy with
      that of imatinib in treating chronic-phase CML patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the time of WBC decreased by 10%,20%,30%,50% of these patients treated
      with these two drugs. II. Compare the time of spleen size decreased by 10%,20%,30%,50% of
      chronic-phase chronic myelogenous leukemia patients treated with imatinib to those treated
      with hydroxyurea pulse therapy. III. Compare the time to achieve complete remission (CR) of
      these patients treated with these two drugs. iv. Estimate the overall survival, event-free
      survival, progression-free survival (OS, EFS, PFS) and major cytogenetic response of these
      patients treated with these two drugs.

      OUTLINE: Patients are to receive one of two treatments. Arm I: Induction: Patients receive
      oral hydroxyurea daily (hydroxyurea pulse therapy) until hematological remission.
      Maintenance: continuing hydroxyurea pulse therapy to maintain white blood cells below 8. 0 ×
      109 / L. Arm II: Induction: Patients receive imatinib 400mg qd until acceptable blood counts
      are achieved. Maintenance: Follow the recommendations of the NCCN guidelines for
      chronic-phase CML treatment.

      PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study within
      2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>white blood cell count</measure>
    <time_frame>2 years</time_frame>
    <description>white blood cell count decreased by 10%, 20%, 30%, 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>spleen size</measure>
    <time_frame>2 years</time_frame>
    <description>spleen size reduced 10%, 20%, 30%, 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission</measure>
    <time_frame>2 years</time_frame>
    <description>the time to achieve complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term efficacy: OS, EFS, PFS</measure>
    <time_frame>5 years</time_frame>
    <description>OS, EFS, PFS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia, Chronic Myeloid</condition>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: hydroxyurea, pulse therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: imatinib, 400mg PO per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
    <description>pulse therapy</description>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <other_name>HU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>400mg qd PO per day</description>
    <arm_group_label>imatinib</arm_group_label>
    <other_name>Imatinib Mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Chronic Myelogenous Leukemia (CML) in chronic phase. Patients in either
             accelerated or blastic phases are not eligible.

          2. No previous therapy with any drugs.

          3. Age ≥ 16 years

          4. Patients with uncontrolled tachyarrhythmias (such as, atrial fibrillation, paroxysmal
             supraventricular tachycardia, and ventricular tachycardias not adequately controlled)
             are not eligible.

          5. Non-pregnant and non-nursing. Treatment under this protocol would expose an unborn
             child to significant risks. Women and men of reproductive potential should agree to
             use an effective means of birth control.

        Exclusion Criteria:

          1. Patients treated with any chemotherapy drugs.

          2. Patients younger than 16 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Zhou, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Zhou, MD, PhD</last_name>
    <phone>008645185555951</phone>
    <email>zhoujin1111@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Zhou, MD, PhD</last_name>
      <phone>008645185555951</phone>
      <email>zhoujin1111@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.</citation>
    <PMID>28416739</PMID>
  </reference>
  <reference>
    <citation>Huang J, Wang L, Chen L, Qun H, Yajing X, Fangping C, Xielan Z. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia. Turk J Haematol. 2017 Mar 1;34(1):10-15. doi: 10.4274/tjh.2016.0156. Epub 2016 Oct 18.</citation>
    <PMID>27751981</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia, Myeloid, Chronic-Phase</keyword>
  <keyword>hydroxyurea</keyword>
  <keyword>Imatinib Mesylate</keyword>
  <keyword>Pulse Therapy, Drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

